Vygenerované: 28.10.2026 20:27:19
Súhrn: The trial was terminated early because of toxicity concerns, and the findings do not establish this combination as a new treatment option for this population METHODOLOGY - Standard chemotherapy is often poorly tolerated in older, frail patients with DLBCL, and because reduced-dose regimens lack randomized evidence, no frontline standard of care has been established for this group Loncastuximab tesirine, a CD19-targeting antibody-drug conjugate, showed promising activity in older patients with relapsed disease in the LOTIS-2 trial, prompting further evaluation.
Doplnenie: Loncastuximab tesirine, a CD19-targeting antibody-drug conjugate, showed promising activity in older patients with relapsed disease in the LOTIS-2 trial, prompting further evaluation.